Redirecting to https://apnews.com/press-release/business-wire/avenzo-therapeutics-granted-fast-track-designation-for-avzo-1418-a-potential-best-in-class-egfr-her3-bispecific-antibody-drug-conjugate-for-the-treatment-of-patients-with-egfr-mutated-tki-pretreated-nsclc-40e2d7d8adbf44919df518205f7abdb4